Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

953
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
953
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.1K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EUS-guided hepaticogastrostomy versus EUS-guided hepaticogastrostomy with antegrade stent placement in patients with unresectable malignant distal biliary obstruction: a meta-analysis of individual patient data.

BMC gastroenterology·2026
Same author

Tattoo Granuloma Associated With Uveitis: A Useful Temporary Entity Pending Further Clarification-Response.

Clinical & experimental ophthalmology·2026
Same author

Expert consensus on fundus fluorescein angiography reporting in ophthalmology: a Delphi study.

The British journal of ophthalmology·2026
Same author

Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum Disorder.

Neurology·2026
Same author

Methodological Limitations in Prognostic Modelling for Refractory Vogt-Koyanagi-Harada Disease: Response.

Clinical & experimental ophthalmology·2026
Same author

Ophthalmic Adverse Events of Systemic Immunotherapy and Targeted Cancer Therapy: A Review.

Clinical & experimental ophthalmology·2026

Related Experiment Video

Updated: Jan 13, 2026

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.5K

Intravitreal Ranibizumab Injections Significantly Influence Retinal Venous Calibre in Patients With Diabetic Macular

Luke K Chehade1,2,3, Noha Ali2,3,4, Paul G Sanfilippo2,3

  • 1Ophthalmology Department, University of Adelaide, Adelaide, South Australia, Australia, adelaide.edu.au.

Journal of Ophthalmology
|January 7, 2026
PubMed
Summary

Intravitreal ranibizumab treatment for diabetic macular edema significantly reduced central retinal vein equivalent (CRVE) and increased artery-to-vein ratio (AVR). This suggests ranibizumab may improve vision by altering retinal vascular calibre.

Keywords:
macular oedemaretinal vesselsvascular endothelial growth factor

More Related Videos

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.3K
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

881

Related Experiment Videos

Last Updated: Jan 13, 2026

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.5K
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.3K
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

881

Area of Science:

  • Ophthalmology
  • Medical Retina
  • Vascular Biology

Background:

  • Diabetic macular edema (DMO) is a leading cause of vision loss in diabetic patients.
  • Intravitreal ranibizumab is a common treatment for DMO, but its effects on retinal vascular calibre are not fully understood.

Purpose of the Study:

  • To evaluate the impact of intravitreal ranibizumab on retinal vascular calibre in patients with DMO.
  • To correlate changes in vascular calibre with visual acuity and macular thickness.

Main Methods:

  • A post hoc analysis of a prospective study involving 76 eyes of 67 treatment-naive patients with DMO.
  • Patients received three monthly ranibizumab injections, followed by pro re nata (PRN) injections.
  • Retinal vascular calibre was measured using digital fundus photographs and a semiautomated program (SIVA), calculating central retinal artery equivalent (CRAE), central retinal vein equivalent (CRVE), and artery-to-vein ratio (AVR).

Main Results:

  • Ranibizumab treatment led to a significant reduction in CRVE at both 2 and 12 months (P < 0.0001 and P = 0.03, respectively).
  • The AVR significantly increased at 2 and 12 months (P = 0.02 and P = 0.01, respectively).
  • Best-corrected visual acuity (BCVA) improved significantly, and central macular thickness (CMT) significantly reduced from baseline to 12 months (P < 0.001 for both).

Conclusions:

  • Intravitreal ranibizumab treatment in DMO patients is associated with a significant decrease in CRVE and an increase in AVR.
  • These vascular calibre changes may contribute to the observed improvements in BCVA and CMT, potentially by reducing retinal venous hydrostatic pressure.